Molecular Partners AG

MOLN

Healthcare|Biotechnology|CH

$3.14

-0.08 (-2.48%)

DCF Value

$2.61

Tangible Book / Share

$1.32

Cash / Share

$1.50

Clinical Trials (16)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07278479 Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors	Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)	P1P2	Recruiting	138	Open-label	[212Pb]Pb-MP0712
NCT07036380 MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma	Advanced Biliary Tract Carcinoma	P2	Recruiting	75	RCT, Open-label	MP0317 + Gemcitabine + Cisplatine + Durvalumab, Gemcitabine + Cisplatin + Durvalumab
NCT05780463 MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)	COVID-19	P3	Completed	485	RCT, Double-blind	MP0420, Placebo, Remdesivir
NCT04828161 A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19	COVID-19	P2P3	Terminated	407	RCT, Double-blind	ensovibep, Placebo
NCT04501978 ACTIV-3: Therapeutics for Inpatients With COVID-19	Covid19	P3	Completed	2,753	RCT, Double-blind	LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
NCT03136653 A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma	Multiple Myeloma in Relapse	P1P2	Completed	33	Open-label	MP0250 plus BOR+DEX
NCT04834856 Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients	Covid19	P2	Completed	12	Open-label	ensovibep
NCT02194426 First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients	Neoplasms	P1P2	Completed	58	Open-label	MP0250
NCT04870164 Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)	COVID-19	P1	Terminated	53	RCT, Double-blind	Ensovibep, Placebo
NCT01086761 Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration	Wet Age-Related Macular Degeneration	P1	Terminated	32	RCT, Open-label	MP0112
NCT03084926 First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors	Neoplasms	P1	Completed	22	Open-label	MP0274
NCT01042678 Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema	Diabetic Macular Edema	P1	Terminated	18	RCT, Open-label	MP0112
NCT05098405 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors	Advanced Malignant Solid Tumor	P1	Terminated	46	Open-label	MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
NCT05673057 Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome	Leukemia, Myeloid	P1	Completed	80	Open-label	MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax, MP0533 with Obinutuzumab pretreatment, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients
NCT03418532 MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC	EGFR-mutated NSCLC (Disorder)	P1	Terminated	8	Open-label	—
NCT04049903 Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	P1	Completed	38	Open-label	MP0310